US Investigator Meeting Held for Ph 3 HLX22-GC-301 in HER2+ Gastric Cancer
Jing Li, Vice President of Global Product Development at Henlius, said: “The U.S. investigator team plays a critical role in trial design interpretation, patient management, and execution quality for HLX22-GC-301. This investigator meeting provided an important platform for alignment and in-depth communication across sites, helping to further enhance consistency and standardization of trial implementation across regions. Henlius will continue to advance global clinical development to the highest standards, working closely with our international investigator partners to accelerate the global clinical validation and value realization of the differentiated innovative asset HLX22.”
Share:
More News
“We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. “This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high
“In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS
“Non-small cell lung cancer is the most prevalent lung disease with more than 8,000 patients in the U.S. diagnosed each year with KRAS G12D-mutations. Receiving Fast Track designation for VS-7375 reinforces both the significant unmet need and the potential of VS-7375 to improve outcomes for patients with KRAS G12D-mutated lung
“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson. “We believe the proprietary Firelink™ platform will overcome